Research programme: progenitor cell chimeric antigen receptor therapy - Nohla TherapeuticsAlternative Names: Progenitor CAR-T cell therapy
Latest Information Update: 12 Jan 2017
At a glance
- Originator Nohla Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Stem cell factors
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 10 Jan 2017 Preclinical trials in Cancer in USA (unspecified route)